Engaging physicians in the evaluation of their preference items is critical. Here are the five primary data sources that when combined, can lead to the greatest success in physician engagement in this work.
Managing, let alone changing, your organization’s block schedule might feel as intimidating as the thought of diving with sharks. But don’t let it scare you; the benefits far exceed the risks. It’s time to dive in!
Health systems and providers continue to face ongoing challenges associated with delivering high-quality, cost-effective care while balancing decreasing reimbursements and new value-based payment models. COVID-19 has heightened the need for organizations to be adaptable, flexible and reliable. Learn why a comprehensive enterprise-wide data-driven strategy is essential to adapting and thriving in this new environment.
The difference in charges for identical services depending on the source of payment is difficult for patients to understand, and even more difficult for providers to explain. With more intense scrutiny on private sector prices arising from higher insurance deductibles and enthusiasm by policymakers over transparency, it is hard to ignore.
As COVID-19 unfolded across the nation, the risk for health systems with an entirely fee-for-service reimbursement system was exposed. Now nine months into the pandemic, it is increasingly clear that COVID-19 may just be the disruptive force that causes those health systems to move decisively toward a reimbursement structure more aligned with value. Here are five value-based care strategies that should be top of mind going into 2021.
A wave of recent press releases and Federal Register notices finalized several outstanding policy goals for President Trump and HHS. Given the late hour, one might ask: will these regulations stand, or will they change once the administration changes in January?
In his latest essay entitled “Bickering in the Back Seat: The Case for All Payer Pricing”, Vizient Research Institute executive director Tom Robertson reminisces about a common childhood memory while contemplating the future direction of health care finance.
When digital breast tomosynthesis was approved for mammography by the Food and Drug Administration in 2011, the 3-dimensional technology brought increased insight into women’s health care, but it did not replace 2D imaging. Instead the two systems complemented each other. Today, however, new technology is poised to change that.
The COVID-19 pandemic, rampant since March, has interrupted life in ways not seen in our country in over a century. With vaccines in development, we just may have a light at the end of the tunnel. The spread of misinformation, the other pandemic, has serious implications for healthcare and no cure in sight.
This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.